Let's create futures. Every day we go to work is a day we might be able to change the world. What better reason is there to get out of bed in the morning? Our secret sauce isn’t much of a secret. We care about people—patients and colleagues alike. So, in our pursuit of life-changing therapies, we make time to connect with each other. Committed, we’re strong. United, we’re formidable. Open Positions One of the major reasons I decided to join the research field was to be able to have a positive impact on someone's life. During my interview at Forma, I could see the commitment of each and every person toward the people living with these life-altering diseases. Somya J. research associate We’re all in. Drug development can be challenging. Being good people and colleagues is easy. You’ll find that our team embraces that philosophy at work and in everyday life. Diversity, Inclusion and Belonging We’re fostering a vibrant community that leads with passion and respect. A place where each employee feels heard and celebrated. To find new ideas, we need all perspectives. Our team works together to understand biotech’s place in building an inclusive and supportive world. 300 North Beacon Street, Suite 501 Watertown, MA 02472 617.679.1970 twitter linkedin instagram facebook glassdoor Privacy Policy Terms of Use © 2021 ALL RIGHTS RESERVED

Myeloid leukemia is considered acute when the inhibition of blood cell production progresses quickly. We’re specifically targeting a large subsection of patients with acute myeloid leukemia who are not achieving remission with existing treatment options. A relapse is the return of cancer after treatment. Relapsed AML affects about 50% of all patients who, following treatment and remission, experience a return of leukemia cells in the bone marrow.2 Refractory AML, which affects between 10% and 40% of newly diagnosed patients, occurs when a patient fails to achieve remission even after intensive treatment.3 Quality of life declines for patients with each successive line of treatment for acute myeloid leukemia, and well-tolerated treatments in relapsed disease remain an unmet need. AML is a relentless disease. There’s significant need to find treatment options for people who aren’t achieving remission or whose cancer has returned. We hope to meaningfully improve quality of life and expectations for these patients. Patrick K. chief medical officer Our selective inhibitor for cancers with IDH1 mutations. In AML, IDH1 mutations inhibit normal cell differentiation and lead to the accumulation of immature myeloid cells. These mutations also cause the excessive production of specific oncometabolites that are linked to the impairment of stem cell differentiation and promotion of cancer cell growth. IDH1 mutations are present in 6-8% of patients with acute myeloid leukemia.4,5 Olutasidenib, an investigational agent, is a selective inhibitor for cancers with IDH1 mutations and is being studied in patients with AML and glioma. 300 North Beacon Street, Suite 501 Watertown, MA 02472 617.679.1970 twitter linkedin instagram facebook glassdoor Privacy Policy Terms of Use © 2021 ALL RIGHTS RESERVED